Considering the disease heterogeneity of NSCLC, the applicability of [64Cu]Cu-DOTA-cetuximab for non-invasive assessment of EGFR expression status in NSCLC warrants further validation in pre-clinical models. This evidence concerns the gene EGFR and non-small cell lung carcinoma.